Full-Time

Senior Medical Science Liaison

Western US, Pegtibatinase

Posted on 4/18/2026

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$173k - $225k/yr

+ Short-Term Incentive + Stock

Remote in USA

Remote

Must reside within Western US territory.

Category
Biology & Biotech (1)
Requirements
  • Advanced degree required (PharmD, PhD, MD/DO, NP, PA or equivalent) in related Life Sciences discipline. Equivalent combination of education and applicable job experience may be considered.
  • Minimum of 5 years' relevant experience as a Medical Science Liaison or equivalent industry/scientific role.
  • Must reside within assigned territory.
  • Ability to travel up to 50+%, including field travel 3-4 days/week, and attend regional/national/international meetings and occasional weekend engagements.
Responsibilities
  • Serve as a regional scientific expert on Pegtibatinase and classical homocystinuria (HCU), delivering impactful scientific exchange with key opinion leaders, health care professionals, and investigators across metabolic and non-metabolic specialties (e.g. neurology, hematology, ophthalmology).
  • Identify, develop, and sustain peer-level relationships with national and regional thought leaders, academic investigators, referring specialists, and other stakeholders in the territories as needed.
  • Foster mutually productive partnerships with KOLs in the areas of medical education and clinical/scientific research and build, cultivate, and leverage relationships with key external scientific and medical customers and organizations in their regions to ensure strong understanding of evolving healthcare trends across the relevant therapeutic area landscape.
  • Serve as scientific expert at key medical and scientific conferences, advisory boards, roundtables, clinical investigator meetings, and internal meetings.
  • Support Phase 3 clinical trial activities in collaboration with Clinical Development and Clinical Operations
  • Engage directly with trial sites to accelerate patient identification, resolve site-level barriers, and facilitate trial execution.
  • Identify sites with additional patients and encourage referral to existing sites or for identification of potentially additional sites for Travere-sponsored clinical trials.
  • Serve as a scientific liaison at investigator meetings and site initiation visits.
  • Assist in the development and implementation of HCP-facing medical education programs and speaker training initiatives.
  • Support creation of educational resources, scientific content, and data-driven slide materials for internal and external use.
  • Contribute to publication planning, disease awareness strategy, and internal upskilling on HCU-related science.
  • Attend international, national, and regional scientific congresses; identify additional regional congresses that may be in line with the overall medical objectives and strategy
  • Support Medical Information activities, support Travere-sponsored activities such as presentations and symposia, gather competitive intelligence and other pertinent activities.
  • Stay current on emerging science, clinical data, and competitive developments in metabolic disease and adjacent fields.
  • Debrief internal teams on key sessions, trends, and insights relevant to medical strategy, evidence generation, and clinical operations.
  • Consistently gather, synthesize, and report actionable field insights to Medical Affairs leadership and cross-functional stakeholders.
  • Leverage structured tools and systems to track feedback on trial design, competitive landscape, HCP sentiment, and access dynamics.
  • Partner with internal teams to ensure insights inform strategic decisions, unmet need assessments, and lifecycle planning.
  • Collaborate with internal partners (Clinical, Commercial, Patient Advocacy, Market Access) to ensure integrated field strategy while upholding medical integrity and regulatory compliance.
  • Support payer and access discussions by providing disease burden context and differentiating clinical data where appropriate.
  • Maintain timely, accurate, and compliant documentation of field interactions and medical insights in accordance with SOPs and corporate standards.
  • Conduct all activities in strict alignment with applicable laws, regulations, and internal compliance requirements.
Desired Qualifications
  • Experience in rare disease, inherited metabolic disorders, or enzyme-replacement therapies preferred.
  • Launch experience preferred.
  • Prior involvement in pre-launch phase, clinical trial support and investigator engagement a plus.
  • Exceptional scientific communication and presentation skills with the ability to distill and convey complex data.
  • Strong organizational, project management, and cross-functional collaboration skills.
  • Ability to build strategic peer-level relationships across diverse specialties and therapeutic areas.
  • Deep understanding of clinical trial processes and stakeholder dynamics.

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI Q1 2026 sales hit $105.2 million, up 88% year-over-year.
  • FSGS approval expands US addressable market beyond 100,000 patients.
  • Chugai submits sparsentan NDA in Japan 2026, triggering milestone payments.

What critics are saying

  • Robbins Geller investigates Travere for securities violations since January 2026.
  • Ligand claims 9% royalty on all worldwide FILSPARI sales.
  • Novartis atrasentan Phase III threatens 20-30% FILSPARI market share.

What makes Travere Therapeutics unique

  • FILSPARI is first FDA-approved therapy for FSGS in patients aged 8 and older.
  • FILSPARI leads IgAN market as most prescribed FDA-approved medicine.
  • Pegtibatinase advances as novel Phase 3 enzyme replacement for classical homocystinuria.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

INACTIVE